Corbus reported topline data from CANYON-1 Phase 1b for CRB-913, an oral CB1 inverse agonist for obesity. At 12 weeks, the 60 mg cohort showed a 5.0% placebo-adjusted weight loss, with fewer GI adverse events than oral GLP-1 drugs and no suicidality observed. The company will present full data at ObesityWeek 2026 and pursue FDA discussions to launch a Phase 2 monotherapy in 2027, with potential combo opportunities.
CRBP received buy ratings from H.C. Wainwright and Oppenheimer this week. Analysts highlight a diversified pipeline as a growth driver. Maldonado believes Novo's drug issues won't affect CRB-913's potential. Oppenheimer targets $88, focusing on CRB-913 and CRB-701. Mizuho views the recent stock drop as an overreaction.
